Free tool
FAERS Monitor: Cyklokapron
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019281 or its brand name (Cyklokapron, Tranexamic Acid). Reports on generic versions are filed under their own applications.
Reports
9,075
Serious
8,437
93% of reports
Hospitalization
4,108
Death reported
1,336
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective662
- off label use657
- pyrexia373
- nausea351
- hypotension340
- diarrhoea319
- haemorrhage317
- vomiting310
- dyspnoea299
- pneumonia282
- febrile neutropenia267
- headache244
- anaemia240
- anaphylactic reaction235
- fatigue230
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 40 |
| 2006 | 41 |
| 2007 | 38 |
| 2008 | 68 |
| 2009 | 76 |
| 2010 | 158 |
| 2011 | 196 |
| 2012 | 191 |
| 2013 | 185 |
| 2014 | 197 |
| 2015 | 285 |
| 2016 | 311 |
| 2017 | 426 |
| 2018 | 485 |
| 2019 | 679 |
| 2020 | 614 |
| 2021 | 854 |
| 2022 | 872 |
| 2023 | 701 |
| 2024 | 951 |
| 2025 | 1,019 |
| 2026 | 647 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,084 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic reactionSignal | 235 | 9.9 | 8.7 | 1,867 |
| febrile neutropeniaSignal | 267 | 9.4 | 8.3 | 1,984 |
| haemorrhageSignal | 317 | 7.0 | 6.3 | 1,642 |
| hypotensionSignal | 340 | 3.9 | 3.5 | 747 |
| anaemiaSignal | 240 | 2.9 | 2.6 | 303 |
| pyrexiaSignal | 373 | 2.5 | 2.3 | 339 |
| pneumoniaSignal | 282 | 2.0 | 1.8 | 146 |
| off label use | 657 | 1.7 | 1.6 | 215 |
| vomiting | 310 | 1.5 | 1.4 | 57 |
| dyspnoea | 299 | 1.2 | 1.1 | 12 |
| drug ineffective | 662 | 1.2 | 1.1 | 16 |
| diarrhoea | 319 | 1.1 | 1.0 | 6 |
| nausea | 351 | 1.0 | 0.9 | 0 |
| headache | 244 | 0.9 | 0.8 | 3 |
| fatigue | 230 | 0.7 | 0.6 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.